RC118-ADC

RC118-ADC (RC118) is an antibody-drug conjugate developed by RemeGen. Its target is Claudin 18.2 (the sponsor names Claudin 18.2). The sponsor states: An antibody-drug conjugate combining a Claudin 18.2-targeting antibody with a microtubule inhibitor payload. ClinicalTrials.gov describes the intervention as: RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT05205850, plans to enrol 135 participants with primary completion expected 2025-09-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.